Neuralink Raises $650 Million to Expand Clinical Trials Across Continents
The company plans to accelerate access to its implantable brain interface through global testing sites and regulatory partnerships.
Silas Davenport 
Neuralink, the brain-computer interface company founded by Elon Musk, has closed a $650 million Series E funding round to support the development and testing of its implantable neural technology. The company aims to use the funding to scale its clinical efforts and enhance the capabilities of its device for patients with severe neurological impairments.
Clinical trials underway in the US, Canada, and UAE
Since its previous funding round in August 2023, Neuralink has been conducting human trials at specialized neurosurgical institutions across three countries. These include the Miami Project to Cure Paralysis at the University of Miami, the Barrow Neurological Institute, Cleveland Clinic Abu Dhabi, and the University Health Network at Toronto Western Hospital in Canada.
According to the company, five individuals with severe paralysis are currently using the Neuralink device to interact with digital and physical systems by relying solely on brain signals. The device is designed to read neuronal activity and translate it into external actions, potentially allowing users to regain a level of independence through thought-driven control.
Investment to drive new technological milestones
The new round was supported by several major investors including DFJ Growth, ARK Invest, Founders Fund, Human Capital, G42, Lightspeed, Qatar Investment Authority (QIA), Thrive Capital, Sequoia Capital, Valor Equity Partners, and Vy Capital.
With this funding, Neuralink intends to increase the number of brain regions and neurons the device can communicate with, which could open the door to future applications in speech, cognition, and motor control.
A company spokesperson emphasized that expanding the device’s interaction with the brain is essential to addressing more complex neurological conditions and unlocking further therapeutic potential.
Regulatory steps and global research efforts
In November 2024, the U.S. Food and Drug Administration (FDA) approved Neuralink’s CONVOY trial, which explores how the implant performs in conjunction with a robotic assistive arm. This study runs alongside the existing PRIME trial in the United States.
The company also received approval from Health Canada for CAN-PRIME, its first international trial. This program will be carried out at Toronto Western Hospital, marking an important step in expanding Neuralink’s research beyond the U.S.
Recently, the FDA granted breakthrough device designation to Neuralink’s brain-computer interface for its potential use in treating individuals with severe speech impairments.
Musk re-engages with core ventures
Following his departure from a special advisory role under former President Donald Trump, Elon Musk has shifted his attention back to his companies, including Neuralink, Tesla, SpaceX, and xAI. His renewed focus signals a continued interest in developing technologies that aim to bridge the gap between biological intelligence and artificial intelligence.
